Rallybio Corp (RLYB)

↓ Download CSV

CIK 0001739410 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Rallybio Corp reported revenue of $858.0K, up 34.9% from the prior year. The company ran a net loss, with a net margin of -1046.4%. It held $62.26M in total assets against $4.30M in total liabilities.

Key ratios (FY2025)

-3853.6%
Operating margin
-1046.4%
Net margin
-15.5%
Return on equity
+34.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$858.0K$636.0K
Operating Income-$33.06M-$60.50M-$78.93M-$67.88M-$45.65M-$25.30M
Net Income-$8.98M-$57.77M-$74.56M-$66.65M-$47.01M-$26.45M
EPS (Diluted)$-1.59$-10.61$-1.84$-2.09$-1.84
Total Assets$62.26M$68.11M$115.62M$180.44M$182.19M$141.86M
Total Liabilities$4.30M$6.45M$9.44M$11.12M$6.58M$5.86M
Shareholders' Equity$57.96M$61.65M$106.18M$169.32M$175.60M$136.00M$16.86M
Cash & Equivalents$31.37M$13.90M$24.49M$56.96M$175.33M$140.23M
Operating Cash Flow-$29.81M-$49.28M-$60.27M-$57.28M-$45.53M-$22.04M
Capital Expenditures$0$12.0K$54.0K$333.0K$137.0K
Shares Outstanding5.28M5.19M37.83M37.84M32.13M23.41M